Literature DB >> 1346066

Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population.

M Caruso1, D Klatzmann.   

Abstract

We have stably expressed in CD4+ lymphoid cells the herpes simplex virus type 1 thymidine kinase (HSV1-TK) gene under the control of the human immunodeficiency virus (HIV) promoter and transactivation response element sequences. Upon HIV infection these regulatory sequences were transactivated, switching on high-level expression of HSV1-TK. This in turn caused the death of HIV-infected cells when they were cultured in the presence of acyclovir, a nucleoside analog that becomes toxic after phosphorylation by HSV1-TK. The elimination of HIV-infected cells resulted in the arrest of HIV spreading in the culture. Complete protection of HSV1-TK-expressing cells was obtained using acyclovir concentrations that are commonly detected in the plasma of patients treated for HSV1 infection. Thus, expression of this DNA construct generates a pool of CD4+ booby-trapped cells that, as a population, are resistant to HIV infection. Our data provide a rationale for the use of suicide genes in the design of gene therapy of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346066      PMCID: PMC48200          DOI: 10.1073/pnas.89.1.182

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Authors:  B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

Review 2.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

4.  Gene therapy in perspective.

Authors:  D J Weatherall
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

5.  Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector.

Authors:  L K Venkatesh; M Q Arens; T Subramanian; G Chinnadurai
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

7.  Cloning of the active thymidine kinase gene of herpes simplex virus type 1 in Escherichia coli K-12.

Authors:  F Colbere-Garapin; S Chousterman; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

8.  Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector.

Authors:  M Poznansky; A Lever; L Bergeron; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

Authors:  G Sczakiel; M Pawlita
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

Review 10.  The CD4 molecule and HIV infection.

Authors:  D R Klatzmann; J S McDougal; P J Maddon
Journal:  Immunodefic Rev       Date:  1990
View more
  20 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  Targeted vectors for gene therapy of cancer and retroviral infections.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

4.  Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein.

Authors:  T Hamouda; R McPhee; S C Hsia; G S Read; T C Holland; S R King
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Recovery of myelin after induction of oligodendrocyte cell death in postnatal brain.

Authors:  Walid Jalabi; Nelly Boehm; Daniel Grucker; M Said Ghandour
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

6.  Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody.

Authors:  L Duan; O Bagasra; M A Laughlin; J W Oakes; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

7.  Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses.

Authors:  H J Brady; C G Miles; D J Pennington; E A Dzierzak
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

8.  Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.

Authors:  Enrico Garaci; Stefano Aquaro; Caterina Lapenta; Alessandra Amendola; Massimo Spada; Sonia Covaceuszach; Carlo-Federico Perno; Filippo Belardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

9.  Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat.

Authors:  L Buonocore; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 10.  Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

Authors:  W Walther; U Stein
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.